N-(tert-butyl)-2-methylpentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(tert-butyl)-2-methylpentanamide
• 英文别名: N-tert-butyl-2-methylpentanamide
• 化学式: C₁₀H₂₁NO
• mdl: MFCD02860249
• 分子量: 171.283
• InChiKey: IMSULPKGOYFTQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-溴戊烷 、 异氰酸叔丁酯 在 1,3-bis[(diphenylphosphino)propane]dichloronickel(II) 、 水 、 sodium t-butanolate 作用下， 以 乙腈 为溶剂， 反应 22.0h， 以64%的产率得到N-(tert-butyl)-2-methylpentanamide
  参考文献：
  名称：

  镍催化的卤代烷，异氰酸酯和H2O的多组分偶联反应：一种获取烷基酰胺的简便方法

  摘要：

  摘要 我们在本文中描述了烷基卤，异氰酸酯和H 2 O的Ni催化的多组分偶联反应，以得到烷基酰胺。稳定的NiCl 2（dppp）能够在温和的反应条件下引发这种转变，从而使操作简便并增加实用价值。底物范围的研究表明，该方案对伯烷基卤和仲烷基卤具有广泛的官能团耐受性和通用性。基于初步实验和先前文献，提出了通过SET过程的合理的催化循环。

  DOI：

  10.1055/s-0040-1707229

文献信息

• Nickel-Catalyzed Reductive Amidation of Unactivated Alkyl Bromides
  作者：Eloisa Serrano、Ruben Martin

  DOI：10.1002/anie.201605162

  日期：2016.9.5

  A user‐friendly, nickel‐catalyzed reductive amidation of unactivated primary, secondary, and tertiary alkyl bromides with isocyanates is described. This catalytic strategy offers an efficient synthesis of a wide range of aliphatic amides under mild conditions and with an excellent chemoselectivity profile while avoiding the use of stoichiometric and sensitive organometallic reagents.

  本文介绍了一种易于使用的镍催化的未活化伯，仲和叔烷基溴化物与异氰酸酯的镍催化还原酰胺化反应。这种催化策略可在温和条件下高效合成各种脂族酰胺，并具有出色的化学选择性，同时避免使用化学计量的和敏感的有机金属试剂。
• COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME
  申请人：Signum Biosciences, Inc.

  公开号：US20170266161A1

  公开（公告）日：2017-09-21

  The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.
• KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：US20210094950A1

  公开（公告）日：2021-04-01

  Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRK1 A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
• US5224987A
  申请人：——

  公开号：US5224987A

  公开（公告）日：1993-07-06
• [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2019183245A1

  公开（公告）日：2019-09-26

  Described herein are compounds having the following structure: formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof. Also disclosed are compositions containing the compounds, methods of inhibiting activity of DYRKl A in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.